Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 562Carcinoma, Non-Small-Cell Lung 482Ovarian Neoplasms 326Lung Neoplasms 203Fallopian Tube Neoplasms 152Neoplasms 150Triple Negative Breast Neoplasms 125Esophageal Neoplasms 125Stomach Neoplasms 121Neoplasm Metastasis 119Carcinoma, Ovarian Epithelial 114Endometrial Neoplasms 95Squamous Cell Carcinoma of Head and Neck 94Uterine Cervical Neoplasms 79Head and Neck Neoplasms 77Esophageal Squamous Cell Carcinoma 77Recurrence 48Adenocarcinoma of Lung 47Parkinson Disease 4, Autosomal Dominant Lewy Body 45Melanoma 42Carcinoma 42Urinary Bladder Neoplasms 41Adenocarcinoma Of Esophagus 36Small Cell Lung Carcinoma 34Carcinoma, Squamous Cell 34Prostatic Neoplasms 31Pancreatic Neoplasms 29Breast Neoplasms, Male 28Unspecified Adult Solid Tumor, Protocol Specific 27Colorectal Neoplasms 25

Interventions

trametinib 1talimogene laherparepvec 1spartalizumab 1pembrolizumab 1nazartinib 1exemestane 1canakinumab 1Telomerase 1Tamoxifen 1Surgical Procedures, Operative 1Specimen Handling 1Sentinel Lymph Node Biopsy 1Pemetrexed 1Paclitaxel 1Mastectomy, Subcutaneous 1Mastectomy, Segmental 1Mammaplasty 1Letrozole 1Indocyanine Green 1Doxorubicin 1Docetaxel 1Brachytherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Ductal × Paclitaxel × Clear all
NCT02779855 2026-03-10

Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Completed
50 enrolled 12 charts
Breast

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Ductal, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡